Research programme: anti-infective and anti-inflammatory therapeutics - Aeolus Pharmaceuticals

Drug Profile

Research programme: anti-infective and anti-inflammatory therapeutics - Aeolus Pharmaceuticals

Alternative Names: AEOL 20415

Latest Information Update: 30 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Jewish Medical and Research Center
  • Developer Aeolus Pharmaceuticals Inc
  • Class
  • Mechanism of Action Immunostimulants; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Pseudomonal infections; Viral infections

Most Recent Events

  • 02 Mar 2017 Aeolus Pharmaceuticals announces intention to submit an IND application for AEOL 20415 to US FDA in the first half of 2017 (Aeolus Pharmaceuticals 10-K, December 2016)
  • 15 Apr 2015 Aeolus Pharmaceuticals in-licenses anti-infective and anti-inflammatory compounds from National Jewish Medical and Research Center
  • 15 Apr 2015 Aeolus Pharmaceuticals files for provisional patent with United States Patent Office for anti-microbial and anti-inflammatory compounds in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top